Plain-English translation of NCT06225193 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research is exploring whether a blood test called the ELF test can reliably detect early signs of liver damage in people who are at risk for fatty liver disease. The study looks at data from patients who already received the ELF test between November 2021 and December 2023 at Methodist Dallas Medical Center to understand how well this simple blood test works in their patient population.
Many patients with fatty liver disease need better screening tools that are simple, affordable, and available in regular doctor's offices. This medication-free blood test could help doctors catch liver problems early and decide which patients need to see a liver specialist, without requiring expensive or invasive procedures like biopsies.
You likely qualify if…
You likely don't qualify if…
This is not an active treatment study. Instead, researchers will review your existing medical records and the ELF blood test results you already had done at Methodist clinics. No new visits or procedures are required—the study simply analyzes data that was already collected to better understand how useful this blood test is for detecting early liver disease.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Enrollment target
~300 participants
Started
June 2023
Primary completion
June 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Crystee Cooper
Methodist Midlothian Medical Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.